$0.08
(Market cap
$2,228 Mln
Recently Viewed
Clear AllMarket cap
$2,228 Mln
Revenue (TTM)
$277 Mln
P/E Ratio
--
P/B Ratio
10.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1
Debt to Equity
1.3
Book Value
$1.4
EPS
$-0.4
Face value
--
Shares outstanding
153,981,561
CFO
$-544.39 Mln
EBITDA
$-889.64 Mln
Net Profit
$-861.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corp (ADPT)
| -14.4 | 1.8 | -25.1 | 88.3 | 17.4 | -20.2 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corp (ADPT)
| 170.9 | 22.1 | -35.9 | -72.8 | -52.5 | 97.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adaptive Biotechnologies Corp (ADPT)
|
13.9 | 2,228.1 | 277.0 | -59.5 | -19.3 | -28.2 | -- | 10.2 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.3 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 87.7 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.9 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 515.1 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 403.4 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.3 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 333.7 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry,... computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Read more
Co-Founder, CEO & Chairman
Mr. Chad M. Robins M.B.A.
Co-Founder, CEO & Chairman
Mr. Chad M. Robins M.B.A.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Adaptive Biotechnologies Corp (ADPT) is $13.90 (NASDAQ) as of 24-Apr-2026 10:36 EDT. Adaptive Biotechnologies Corp (ADPT) has given a return of 17.4% in the last 3 years.
Since, TTM earnings of Adaptive Biotechnologies Corp (ADPT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-41.80
|
11.37
|
|
2024
|
-5.53
|
4.35
|
|
2023
|
-3.15
|
2.30
|
|
2022
|
-5.46
|
2.35
|
|
2021
|
-19.12
|
6.56
|
The 52-week high and low of Adaptive Biotechnologies Corp (ADPT) are Rs 20.76 and Rs 7.16 as of 24-Apr-2026.
Adaptive Biotechnologies Corp (ADPT) has a market capitalisation of $ 2,228 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Adaptive Biotechnologies Corp (ADPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.